Renal cancer in kidney transplanted patients
Renal cancer occurs more frequently in renal transplanted patients than in the general population, affecting native kidneys in 90% of cases and the graft in 10 %. In addition to general risk factors, malignancy susceptibility may be influenced by immunosuppressive therapy, the use of calcineurin inhibitors (CNI) as compared with mammalian target of rapamycin inhibitors, and the length of dialysis treatment. Acquired cystic kidney disease may increase the risk for renal cancer after transplantation, while autosomal dominant polycystic kidney disease does not seem to predispose to cancer development. Annual ultrasound evaluation seems appropriate in patients with congenital or acquired cystic disease or even a single cyst in native kidneys, and every 2 years in patients older than 60 years if they were on dialysis for more than 5 years before transplantation. Immunosuppression should be lowered in patients who develop renal cancer, by reduction or withdrawal of CNI. Although more evidence is still needed, it seems reasonable to shift patients from CNI to everolimus or sirolimus if not already treated with one of these drugs, with due caution in subjects with chronic allograft nephropathy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Journal of nephrology - 28(2015), 6 vom: 26. Dez., Seite 659-68 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Frascà, Giovanni M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.07.2016 Date Revised 03.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40620-015-0219-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM251147819 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM251147819 | ||
| 003 | DE-627 | ||
| 005 | 20231224161355.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40620-015-0219-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0837.xml |
| 035 | |a (DE-627)NLM251147819 | ||
| 035 | |a (NLM)26202137 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Frascà, Giovanni M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Renal cancer in kidney transplanted patients |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.07.2016 | ||
| 500 | |a Date Revised 03.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Renal cancer occurs more frequently in renal transplanted patients than in the general population, affecting native kidneys in 90% of cases and the graft in 10 %. In addition to general risk factors, malignancy susceptibility may be influenced by immunosuppressive therapy, the use of calcineurin inhibitors (CNI) as compared with mammalian target of rapamycin inhibitors, and the length of dialysis treatment. Acquired cystic kidney disease may increase the risk for renal cancer after transplantation, while autosomal dominant polycystic kidney disease does not seem to predispose to cancer development. Annual ultrasound evaluation seems appropriate in patients with congenital or acquired cystic disease or even a single cyst in native kidneys, and every 2 years in patients older than 60 years if they were on dialysis for more than 5 years before transplantation. Immunosuppression should be lowered in patients who develop renal cancer, by reduction or withdrawal of CNI. Although more evidence is still needed, it seems reasonable to shift patients from CNI to everolimus or sirolimus if not already treated with one of these drugs, with due caution in subjects with chronic allograft nephropathy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Calcineurin inhibitors | |
| 650 | 4 | |a Immunosuppressive therapy | |
| 650 | 4 | |a Renal cancer | |
| 650 | 4 | |a Renal transplantation | |
| 650 | 4 | |a mTOR inhibitors | |
| 650 | 7 | |a Calcineurin Inhibitors |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a MTOR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.1 |2 NLM | |
| 650 | 7 | |a TOR Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Sandrini, Silvio |e verfasserin |4 aut | |
| 700 | 1 | |a Cosmai, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Porta, Camillo |e verfasserin |4 aut | |
| 700 | 1 | |a Asch, William |e verfasserin |4 aut | |
| 700 | 1 | |a Santoni, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Salviani, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a D'Errico, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Malvi, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a Balestra, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Gallieni, Maurizio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nephrology |d 1995 |g 28(2015), 6 vom: 26. Dez., Seite 659-68 |w (DE-627)NLM08977650X |x 1724-6059 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2015 |g number:6 |g day:26 |g month:12 |g pages:659-68 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40620-015-0219-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2015 |e 6 |b 26 |c 12 |h 659-68 | ||